Introduction {#S1}
============

Autoimmune diseases are the consequences of an abnormal immune response in the form of autoantibodies and T-cells attacking the host's body. These diseases include both tissue-specific and systemic disorders and affect approximately 3--5% of the population ([@B1], [@B2]). Most of the autoimmune diseases are heterogeneous in nature and are usually characterized by the expression of autoantibodies, pro-inflammatory cytokines, and autoreactive T-cells ([@B3], [@B4]). Many theories have suggested that a genetic predisposition is the main cause of autoimmune diseases. However, the concordance rates of autoimmune disease in monozygotic twins range from 12 to 67% ([@B2], [@B5]). Furthermore, in an *in vivo* study, collagen-induced arthritis in inbred mice of the single cage, which were comparable to identical twins, affected a minority ([@B5]). These studies give evidence that heredity accounts for only approximately one-third of the risk of developing an autoimmune disease, while environmental and epigenetic factors account for the majority of the risk ([@B6]). Many environmental factors, including microbial infection, chemicals exposure, free radicals, abnormal blood glucose, cholesterol, and inflammation are known to trigger autoinflammation ([@B7]--[@B13]). All of these factors are also known to induce endoplasmic reticulum (ER) stress ([@B14], [@B15]), indicating the possible association of ER stress to the onset of the autoimmune diseases. Further, several recent studies have shown that ER stress precedes the progression of autoimmune diseases ([@B16]--[@B18]). In addition, ER stress can lead to the upregulation of many pro-inflammatory cytokines, including TNFα, IL-1β, IFN-γ, IL-6, and IL-23 ([@B19]), which comprise the hallmark of autoimmune diseases ([@B20]). In spite of significant development has been made in the treatments using immunosuppressive or immunomodulatory agents, the prognosis is still poor for many patients in terms of a long-term cure ([@B5]). Therefore, clear knowledge on the mechanisms that are responsible for dysregulation of the immune system, which in turn leads to autoimmune disease, will help in developing therapeutics. Additionally, knowledge about the precise causes for the elicitation of the autoimmune response, especially ER stress-mediated immune response is required for developing treatment modalities, but these causes are still unclear.

How Does ER Function Contribute to Autoimmune Diseases? {#S2}
=======================================================

The ER controls multiple cellular functions involving protein folding, post-translational modifications (PTMs), fatty acid biosynthesis, detoxification, and also stores the intracellular calcium ([@B21]). About one-third of cellular proteins majorly including secretory and transmembrane proteins reach maturation in the ER ([@B22], [@B23]). Once ribosomes translate the mRNA, the synthesized peptide is inserted into the ER based on its signal sequence. The signal sequence is then cleaved, and the protein is moved into the lumen of the ER. Inside the lumen, it is folded into its functional conformation and remains in the ER or, through the Golgi bodies, is transported to other cellular organelles or cytoplasmic membrane or is secreted. However, regardless of its destination, newly synthesized proteins undergo various processes in the lumen of the ER ([@B24]). These processes include folding, formation of multisubunit complexes, disulfide bond formation, N-glycosylation, and many other PTMs ([@B25]). In addition, the ER has been implicated in metabolism of glucose, lipids, and cholesterol, and also in the process of autophagy ([@B22]).

As the functions of the ER required, the environment in the ER is oxidative and rich in calcium and other protein folding machineries ([@B26]). The protein folding requirement and degree of secretory protein synthesis vary across cell types. Cells with secretory functions, such as pancreatic β cells and liver cells are rich in ER to meet the high, fluctuating demand ([@B27], [@B28]). Inside the ER, secretory proteins are folded precisely to their native conformations with the assistance of chaperones and protein disulfide isomerases (PDI), and then the properly folded proteins translocate to their destined place based on the signal sequence ([@B21], [@B29]). However, cells can encounter conditions, such as viral infections, cancers, neurodegenerative diseases, diabetes, inflammation, a high demand of secretory proteins, and other aberrations at the cellular level during which ER protein folding functions can be disturbed ([@B30]). This can result in the accumulation of unfolded proteins inside the ER, entitled as ER stress ([@B30]--[@B32]). However, cells have developed a mechanism to sense these changes and try to reestablish homeostasis by stimulating specific signal transducing pathways, named as the unfolded protein response (UPR) ([@B33], [@B34]). This process is well conserved from yeast to humans ([@B35]).

The UPR system initially tries to restore homeostasis through transcriptional induction of folding enzymes, chaperones, oxidoreductases, reduced translation, autophagy, lipid biogenesis, vesicular trafficking, degradation of ER-associated mRNA, and degradation of unfolded proteins through ER-associated protein degradation (ERAD) ([@B36]). However, this adaptive process may fail, due to persistent stress resulting from a high demand for proteins, especially in secretory cells, and due to chronic diseases ([@B37]). In that case, the activated UPR transforms it signals from survival to a death inducing pathway to clear the affected cells from the system ([@B38]). However, unrestricted apoptosis leads to a loss of cells in organs ([@B38], [@B39]). These pro-death signaling pathways cause the pathogenesis of many diseases through increasing reactive oxygen species (ROS), activating proapoptotic proteins, and activating inflammatory molecules ([@B40]).

In addition to the secretion of inflammatory cytokines, disturbances in the ER environment result in abnormal PTM of many proteins, which can activate the autoimmune response by developing into neoantigens ([@B41]). The ER stress-mediated generation of autoantigens/neoantigens is reviewed elsewhere ([@B42], [@B43]). Indeed, several ER proteins, including insulin, glucose-regulated protein 78 (GRP78), glutamic acid decarboxylase 65, and chromogranin A are turned into neoantigens due to abnormal PTM ([@B41], [@B44], [@B45]). These neoantigens activate autoreactive T-cells, which leads to pathological conditions ([@B46]). Furthermore, in rat insulinoma (INS-1E) cells and non-obese diabetic (NOD) mice, cytokine-induced ER stress produces the post-translationally modified chaperone protein GRP78 or immunoglobulin binding protein (BiP) ([@B47], [@B48]). This modified GRP78 generates autoreactive T-cells with higher levels of IL-17, TNFα, and IFN-γ production ([@B17], [@B49]). The cytokine-mediated calcium depletion in the ER also activates the cytosolic calcium-dependent PTM enzymes transglutaminase 2 (Tgase2) and peptidylarginine deiminases, which generate the neoantigens ([@B50]). In addition, ER stress-mediated UPR upregulates the production of the important pro-inflammatory cytokines, such as IL-1β, TNFα, IL-17, and IL-23, which further enhance the tissue damage ([@B51]). These cytokines are known to contribute significantly in the pathogenesis of autoimmune disorders ([@B52], [@B53]). Interestingly, cytokines, in a feedback loop mechanism can induce ER stress and apoptosis through the UPR ([@B54]). Taken together these discoveries imply the contribution of ER stress to the development of autoimmune diseases. In this review, we center on the implications of the conserved ER stress-transducing molecule IRE1α in the onset and pathogenesis of autoimmune diseases. We especially consider its role in immune cells and its signaling pathways in the immune response, along with potential IRE1α targeting therapies to treat autoimmune diseases.

IRE1α/ERN1 (Inositol-Requiring Enzyme1/Endoplasmic Reticulum to Nucleus1) {#S3}
=========================================================================

IRE1α, the most evolutionarily conserved ER membrane protein regulates, many cellular processes involving cell survival and cell death ([@B55]--[@B57]). The IRE1 gene was first identified in yeast in the search of genes involved in the metabolism of inositol phospholipids; it complemented a yeast mutant requiring exogenous inositol for its growth ([@B58]). Later, from the benchmark work of Peter Walter and Kazutoshi Mori, IRE1 was identified as a UPR molecule through the screening of yeast genes involved in signal transduction from the ER to the nucleus during misfolded protein accumulation ([@B59], [@B60]). In metazoans, IRE1 exists in two isoforms: IRE1α/ERN1 and IRE1β/ERN2. IRE1α is localized to the ER membrane and has an N-terminal signal-sensing ER luminal domain (LD), a type I transmembrane domain (TD) and a dual enzymatic, hydrophilic, cytosolic C-terminal domain having both kinase and endoribonuclease functions ([@B61]). IRE1α is prevalent in almost all tissues, but IRE1β is expressed only in intestinal epithelial cells (IECs) ([@B62]) and airway mucous cells ([@B63]). The amino acid sequence of the sensor, kinase, and RNase domains (RDs) of human IRE1α and IRE1β have 48, 80, and 61% identity, respectively ([@B64]).

Activation Mechanism of IRE1α During ER Stress and Its Downstream Signals {#S3-1}
-------------------------------------------------------------------------

The disturbed environment in the ER during pathological conditions and also at a low level in regular physiological conditions, leads to the activation of IRE1α ([@B65]) (Figure [1](#F1){ref-type="fig"}A). In normal conditions, it is negatively regulated by the attachment of the ER chaperonic protein BiP, on the ER LD of IRE1α ([@B66], [@B67]). However, during the accumulation of misfolded proteins, BiP separates and binds to the misfolded proteins due to its higher affinity for these proteins than IRE1α ([@B68]). The dissociation of BiP leads to self-association of IRE1α's LD, causing IRE1α to dimerize and trans-autophosphorylate its cytoplasmic kinase domain ([@B69]). This leads to conformational change in the RD, which then becomes enzymatically active, and also forms higher order oligomers ([@B69]--[@B73]). It was reported recently that misfolded proteins can also bind directly to IRE1α and similarly activate it ([@B74]). In addition, membrane aberrancy, alteration in the cellular lipid composition and membrane lipid saturation also activate IRE1α through its TDs ([@B75]--[@B77]). Upon the activation of its kinase and endoribonuclease functions, IRE1α takes out an intron of 26 nucleotide length from X-box binding 1 (*XBP1*) mRNA by an unconventional method in the cytoplasm: specifically, in a spliceosome-independent manner, leading to introduction of a new termination codon due to a frame-shift in the coding sequence ([@B78], [@B79]). The IRE1α endoribonuclease activity gives rise to two free ends of 2′3′-cyclic phosphate and 5′-OH at 5′ and 3′exons, respectively ([@B80]). However, this endoribonuclease activity depends on the presence of a specific pair of appropriate stem-loop structures and a conserved consensus sequence, CNCNNGN (where N is any base) in the mRNA ([@B55], [@B81]). These ends are ligated by tRNA ligase, RtcB, generating the stable transcription factor XBP1 (XBP1s) ([@B82]) (Figure [1](#F1){ref-type="fig"}B). XBP1s targets many genes involved in multiple cellular functions and this activity varies with cell type and condition ([@B83]). In particular, XBP1s induce the expression of proteins involved in ER stress attenuation: protein folding chaperone GRP78, PDI, and translocation proteins ([@B84], [@B85]). In addition, XBP1s promotes the expression of the ER quality-control proteins heat shock protein 40 kDa (DnaJ), p58, ER-resident molecule (ERdj4), ER degradation-enhancing α-mannosidase-like protein (EDEM) involved in ERAD, and ER-to-Golgi transport components ([@B81], [@B86]--[@B88]). Further, XBP1s is necessary for basic physiological functions, mainly in secretory and differentiating cells ([@B89]--[@B91]), and also contributes to inflammation ([@B92]). IRE1α is also inevitable for the placental and embryonic development. Lacking of IRE1α in mice resulted in embryonic mortality during gestation, due to liver hypoplasia and reduced angiogenesis ([@B93]).

![IRE1α structure and its downstream mechanisms in mild and severe stress. **(A)** A model depicting the IRE1α structure and its functional domains: luminal domain (LD), transmembrane domain (TD), linker region (LR), kinase domain (KD), RNase domain (RD), and an activation loop at the KD. **(B)** Stress factors, such as mutations, high demand for secretory proteins, ionic imbalance, and disease cause an accumulation of misfolded proteins, leading to activation of the unfolded protein response. Immunoglobulin binding protein regulates IRE1α through dimerization, autophosphorylation, and further oligomerization. During mild endoplasmic reticulum (ER) stress, activated IRE1α helps the cells to recover from stress through increasing the ER folding chaperones and ER-associated degradation (ERAD) components by generating stable transcription factor XBP1s, as follows: active IRE1α cleaves *XBP1* mRNA, and the cleaved fragments are ligated by RtcB. Stable XBP1 mRNA is generated and translated to form the transcription factor XBP1s, which moves to the nucleus and induces the expression of chaperone proteins and ERAD process-associated genes. Another process, regulated IRE1α-dependent decay (RIDD), degrades mRNAs and reduces the load of new proteins entering ER, which helps in cell survival; in addition, the generation of small RNA fragments triggers the inflammatory response. **(C)** With severe stress, IRE1α induces the alternative pathway: apoptotic signaling by recruiting TNF receptor-associated factor 2 (TRAF2) and apoptosis signaling kinase1, leading to c-Jun N-terminal kinase (JNK) phosphorylation. Phosphorylated JNK induces apoptosis through many signaling pathways. It causes the proapoptotic proteins Bcl-2-associated X protein (BaX), and Bim to translocate to the mitochondrial membrane by inhibiting antiapoptotic B-cell lymphoma family 2 (Bcl-2). The mitochondrial membrane is ruptured, and cytochrome C is released, which activates caspase-9 and -3, which in turn cleave many proteins and cause cell death. Phosphorylated JNK also translocates Sab protein, which increases the mitochondrial reactive oxygen species (ROS) and leads to cell death directly, as well as ROS inducing inflammation-mediated cell death. In addition, JNK-mediated transcription factor AP-1 induces pro-inflammatory cytokine-mediated cell death. IRE1α also can induce inflammation-mediated cell death by activating NFκB. Furthermore, RIDD activity, which degrades prosurvival mRNAs, which increases caspase-2 expression, causes translocation of BH3-interacting domain to the mitochondria, and also degrades miRNA17, which stabilizes the thioredoxin-interacting protein thioredoxin-interacting protein, leading to inflammation and ROS-mediated cell death. In addition, spliced XBP1s stimulates the expression of the proapoptotic protein CCAAT-enhancer-binding protein homologous protein (CHOP), which induces cell death. Finally, IRE1α/TRAF2 association can activate caspase-12-mediated cell apoptosis.](fimmu-09-01289-g001){#F1}

In addition to the generation of a stable XBP1s transcription factor, IRE1α activation causes the cleavage of other ER-localized mRNAs, cytosolic mRNAs, ribosomal RNA, and miRNAs, leading to their degradation in a process named as regulated Ire1-dependent decay (RIDD) ([@B94]--[@B97]) (Figure [1](#F1){ref-type="fig"}B). This cleavage activity is also sequence specific, but it does not necessarily require a double-loop structure, unlike in XBP1 splicing ([@B55], [@B56]). RIDD function helps in ER stress reduction, due to decreasing in the inflow of newly synthesized proteins into the ER, and it also participates in biological functions, such as glucose metabolism, inflammation, and apoptosis ([@B55]). In addition, cleaved mRNA fragments generate an inflammatory response ([@B98]). Notably, RIDD is hyperactivated under conditions of XBP1 deficiency and is implicated in both cell survival and death depending on the nature of tissue and level of stress intensity ([@B19], [@B99], [@B100]). Interestingly, another isoform, IRE1β, is primarily involved in RIDD activity but is less active in generating XBP1s compared with IRE1α and mediates the protein-folding process in lung and gut epithelial secretory cells ([@B63], [@B101]).

IRE1α-Mediated Cell Apoptosis Pathways Involved in Pathogenesis {#S3-2}
---------------------------------------------------------------

IRE1α induces the cell death pathway by activating different apoptosis-inducing molecules through its endonuclease and kinase functions (Figure [1](#F1){ref-type="fig"}C). However, this action of IRE1α is highly controlled or restricted, depending on the level and type of stress or tissue origin ([@B102], [@B103]). IRE1α activity is necessary for the normal functions of the cells and also for the stress adaptive process ([@B104]). However, when a threshold reached in terms of the balance of survival and death signals, IRE1α activates the cell death signaling, which is regulated by its regulating partner molecules ([@B34], [@B105]). IRE1α triggers cell death by promoting the intrinsic apoptosis pathway through interaction with a hub of diverse molecules through TNF receptor-associated factor 2 (TRAF2) ([@B40]). IRE1α and TRAF2 association forms a complex with apoptosis signaling kinase 1 (ASK1) and phosphorylate c-Jun N-terminal kinase (JNK) ([@B106]--[@B108]). The phosphorylated JNK induces the apoptotic signal through many pathways. Sustained JNK activation is known to trigger apoptosis by regulating specific proteins of the B-cell lymphoma family 2 (Bcl-2) ([@B40], [@B109], [@B110]), which activates the cytochrome C-mediated apoptotic pathway. JNK translocates to the mitochondrial membrane and promotes apoptosis by phosphorylating and inhibiting the anti-apoptotic Bcl-2 proteins ([@B111]--[@B113]). In addition, it promotes the localization of the Bcl-2-associated X protein (BaX) and Bcl-2-associated death promoter (BaD) proapoptotic proteins to the mitochondria; this damages the mitochondrial membrane, leading to release of cytochrome C, which consequently activates the caspase-9 and -3, inducing cell death. Additionally, BaD can antagonize anti-apoptotic Bcl-2 proteins, thus promoting apoptosis ([@B110], [@B111], [@B113]). Furthermore, activated JNK binds to Sab (SH3 homology-associated BTK binding protein) on the outer mitochondrial membrane, which promotes mitochondrial ROS production and induces cell death ([@B114]). JNK activation also mediates cell death through AP-1-mediated expression of pro-apoptotic genes ([@B115]--[@B117]). IRE1α/TRAF2 association is also implicated in the induction of the pro-apoptotic signaling pathway through caspase-12 activation ([@B118], [@B119]). Interestingly, receptor-interacting serine/threonine protein kinase 1 (RIPK1) stimulates the IRE1α-mediated JNK activation *via* a TNF-independent interaction of tumor necrosis factor receptor 1 on the ER membrane ([@B120], [@B121]). The association of receptor-interacting serine/threonine protein kinase 1 (RIPK1) and IRE1α also promotes death receptor-independent caspase-8 activation, which then induce cell death through activating caspase-9 and caspase-3-mediated cell damage. Additionally, the IRE1α/TRAF2 interaction promotes NFκB-dependent autocrine production of TNFα and apoptosis ([@B122], [@B123]). In addition, IRE1α/XBP1s also induce apoptosis of hepatocytes in an ER stress-dependent manner by inhibiting Akt through increasing Pleckstrin homology like domain family A member 3 (PHLDA3) expression ([@B124]). In addition, XBP1s also enhance CCAAT-enhancer-binding protein homologous protein (CHOP)-mediated cell death ([@B125]).

Furthermore, the IRE1α-mediated RIDD process has also been implicated in cell apoptosis ([@B55]). During hyper-activation, IRE1α degrades cell-essential mRNA, which leads to reduced survival. RIDD activity also contributes to mitochondrial apoptotic pathway through caspase-2 and BH3-interacting domain activation by degrading the caspase-2 repressing miRNA, resulting in enhanced expression and activation of caspase-2 ([@B126], [@B127]). In addition, IRE1α degrades miRNA-17, a repressor of thioredoxin-interacting protein (TXNIP), resulting in TXNIP-mediated activation of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome, and its caspase-1 and caspase-2-dependent pro-death pathways ([@B128], [@B129]).

IRE1α in Immune Cells {#S4}
=====================

The role of IRE1α in immune functions is being progressively identified as a possible mechanism for multiple complex immune-related diseases ([@B130]). Primarily, IRE1α plays a very important role in the survival and functioning of many immune cell types ([@B131]). Due to their secretory function, immune cells have larger ER with higher protein-folding activity, and consequently they are more susceptible to agents, such as toxins, diseases, and pathogens that induce ER stress ([@B132]). This may necessitate the presence of IRE1α in immune cells. In addition to the pathophysiological effects, IRE1α activation plays an important function in the normal physiology of immunologically important cell types. The functional requirements of IRE1α in different immune cell types are summarized in Table [1](#T1){ref-type="table"}.

###### 

IRE1α functions in different immune cells.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Immune cell                  Functions of IRE1α                                                                                                                                                                                                                                         Reference
  ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  B cells and plasma cells     IRE1α and XBP1s are required for the terminal differentiation of B cells to plasma cells\                                                                                                                                                                  ([@B53], [@B89], [@B133], [@B134])
                               IRE1α is required for the expansion of the endoplasmic reticulum (ER) and antibody production and secretion during both physiological and pathological immune responses                                                                                    

  T cell                       IRE1α and XBP1s are active in early stages of T-cell, in bone marrow pro-B cells, CD4^+^ T-cells, CD8^+^ thymic T-cells, CD8^+^ splenic T-cells, and cytotoxic T-cell\                                                                                     ([@B135]--[@B139])
                               XBP1s is also required for the terminal differentiation of CD8^+^-effector T-cells\                                                                                                                                                                        
                               Active XBP1s was found in CD8^+^ T-cells in acute infection with *Listeria monocytogenes*                                                                                                                                                                  

  Dendritic cells (DCs)        IRE1α and XBP1s were found constitutively active in DCs\                                                                                                                                                                                                   ([@B135], [@B139]--[@B142])
                               Loss of XBP1s leads to significantly reduced numbers of both conventional and plasmacytoid DCs\                                                                                                                                                            
                               XBP1s deficiency in DCs increased the rate of apoptosis\                                                                                                                                                                                                   
                               IRE1α/XBP1s-induced lipid accumulation in DCs impaired MHC class I-mediated antigen presentation to cytotoxic T-cells\                                                                                                                                     
                               Loss of XBP1s in splenic type 1 conventional dendritic cells (cDC1s) resulted in functional alterations, but also impaired the survival of mucosal cDC1s\                                                                                                  
                               Loss of XBP1s in CD8α^+^ DCs led to defects in phenotype and MHC class I antigen presentation                                                                                                                                                              

  Granulocytes (eosinophils)   Hematopoietic deletion of XBP1s in mice led to the loss of fully mature eosinophils\                                                                                                                                                                       ([@B143])
                               Loss of XBP1s specifically in eosinophils led to a significantly smaller pool of eosinophils in the bone marrow and reduced eosinophil differentiation\                                                                                                    
                               XBP1s is needed for the sustained viability of eosinophils                                                                                                                                                                                                 

  Macrophages                  IRE1α and XBP1s are crucial for optimal and sustained production of pro-inflammatory cytokines in macrophages\                                                                                                                                             ([@B144], [@B145])
                               Macrophage-specific loss of XBP1 impairs the production of IL-6, TNFα, IFN-β, IL1-β, and C-C motif chemokine ligand 2 (CCL2)\                                                                                                                              
                               IRE1α functions in macrophage polarization                                                                                                                                                                                                                 

  Hematopoietic cells          IRE1α and XBP1s play a role in the cell cycle and differentiation of hematopoietic cell                                                                                                                                                                    ([@B146])

  Monocytes                    XBP1s and its downstream chaperone immunoglobulin binding protein are involved in the differentiation of monocytes into macrophages\                                                                                                                       ([@B147], [@B148])
                               The IRE1α/XBP1s pathway has importance in the development of monocytes into osteoclasts in response to RANKL                                                                                                                                               

  Neutrophils                  IRE1α function is required for neutrophil infiltration\                                                                                                                                                                                                    ([@B149])
                               Knockdown of XBP1 in neutrophils impaired the release of granules                                                                                                                                                                                          

  Natural killer (NK) cell     Expression of XBP1s was observed in the initiation of NK cell-mediated direct cytotoxicity or antibody-dependent cell-mediated cytotoxicity (ADCC) in leukemia or lymphoma target cells\                                                                   ([@B150])
                               Pharmacological inhibition of the IRE1α/XBP1s pathway significantly impaired both NK cell-mediated direct-cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). This indicates that XBP1s is essential for optimal NK cell cytotoxicity   

  Mast cells                   IRE1α may involve mast cell functions. Since, application of IRE1α-specific inhibitor, 8-formyl-7-hydroxy-4-methylcoumarin, in mast cells reduced the IgE-mediated degranulation of mast cells as well as release of cytokines, such as TNF-α and IL-4     ([@B151])

  Paneth cells                 XBP1s is necessary for Paneth cell development in the gut\                                                                                                                                                                                                 ([@B92])
                               XBP1 deletion caused Paneth cell dysfunction and increased susceptibility to enteritis and induced colitis in intestinal epithelial cells                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IRE1α-Mediated Immune Response {#S4-1}
------------------------------

Endoplasmic reticulum stress, as well as cytokine-mediated IRE1α activation with its kinase and RNase properties, triggers the immune response through various downstream pathways depending on the tissue types. These pathways are involved in pathogenesis of various diseases (Figure [2](#F2){ref-type="fig"}). Activation of IRE1α in immune cells and other stromal cells induces the secretion of many cytokines, such as IL-1β, IL-6, IL-23, IFN-β, and TNFα ([@B40], [@B172], [@B173]). The kinase function of IRE1α in association with TRAF2 mediates phosphorylation of JNK (p-JNK). Then, p-JNK interacts with Fos and forms the AP-1 transcription factor ([@B115]), which increases the gene expression of pro-inflammatory cytokine IL-6 ([@B40], [@B174]). In addition, IRE1α can activate the pattern recognition receptors, which include the nucleotide-binding oligomerization domain containing proteins 1 and 2 (NOD1/2). This causes the release of IL-6 through receptor-interacting serine/threonine-protein kinase 2 (RIPK2) ([@B175]). Furthermore, activated IRE1α triggers IκBα kinase (IKK)-mediated phosphorylation of IκBα (the inhibitor of NFκB), leading to its degradation, NFκB activation, and further release of TNFα and interleukins (ILs) ([@B122], [@B176], [@B177]).

![IRE1α regulates the immune function through various mechanisms including both its kinase **(A)** and RNase **(B)** functions. **(A)** Endoplasmic reticulum (ER) stress-activated, serine/threonine-protein kinase/endoribonuclease IRE1α binds to TNF receptor-associated factor 2 (TRAF2), apoptosis signaling kinase1 (ASK1), and receptor-interacting serine/threonine protein kinase 1 (RIPK1), resulting in phosphorylation of c-Jun N-terminal kinase. Then c-Jun interacts with c-Fos forms the active transcription factor AP-1, and increases the production of IL-6 and TNFα. Furthermore, the IRE1α/TRAF2/ASK1 complex activates the inhibitory kappa B kinase (IKK), which phosphorylates inhibitor of kappa B (IκB), leading to release of NFκB and its translocation to the nucleus, where it induces the expression of cytokines. The dissociated IκB is then degraded by proteasomes. The IRE1α--TRAF2 complex increases IL-6 production *via* the association of nucleotide-binding oligomerization domain (NOD)-containing proteins 1 and 2 (NOD1 and NOD2) and receptor-interacting serine/threonine-protein kinase 2 (RIPK2). **(B)** IRE1α through its RNase function generates splices---X-box-binding protein 1 (XBP1s) transcription factor induces the expression of several pro-inflammatory cytokines and also decreases MHC class I antigen presentation. In addition, XBP1s increases NFκB nuclear translocation by mediating the degradation of FoxO1, an inhibitor of NFκB. Furthermore, IRE1α activation differentially regulates the expression of the pro-inflammatory cytokine IL-1β gene *via* activation of glycogen synthase kinase-3β. The regulated IRE1α-dependent decay (RIDD) degrades miR-17, leading to an increase in thioredoxin-interacting protein expression. This in turn activates nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activity, which leads to procaspase-1 cleavage, which subsequently activates IL-1β, IL-18, and IFN-β, and also increases the Th-cell 1 immune response. RIDD generates small fragments of RNA, which activate the retinoic inducible gene-I and mitochondrial antiviral protein, increasing IFNβ production *via* NFκB. In addition, RIDD reduces the *TAPBP* mRNA level, leading to decreased antigen presentation. Toll-like receptors 2, 4, and 7 and other cytokines can directly activate the IRE1α/XBP1s pathway without ER stress and cause the release of many pro-inflammatory cytokines.](fimmu-09-01289-g002){#F2}

The RNase activity of IRE1α causes the release of pro-inflammatory cytokines through both the XBP1s and RIDD pathways. The IRE1α/XBP1s pathway is activated during TLR3, TLR4, and TLR7 ligand stimulation during pathogenesis inducing the type I interferons (IFNs), IFN-α and IFN-β genes expression and furthering the pathogenesis of autoimmune and inflammatory diseases ([@B178], [@B179]). In one study, knockdown or inhibition of IRE1α as well as XBP1 reduced the production of IL-1β in primary airway epithelial cells and the production of IL-1β along with the chemokine, C-C motif chemokine ligand 2 (CCL2), in macrophages ([@B145], [@B180]). In a study of apolipoprotein E (ApoE) knockout mice, IRE1α inhibition with 8-formyl-7-hydroxy-4-methylcoumarin (4μ8c) markedly suppressed the T-helper-1 (Th-1) immune responses, as evidenced by decreased IFN-γ ([@B145]). This outcome was mediated through the inhibition of the NLRP3 inflammasome, which otherwise stimulates the secretion of IL-1β and IL-18, cytokines known to generate Th-1-type immune responses ([@B145], [@B181]--[@B183]); this might have implications toward the autoimmune response ([@B181]). In addition, in a study of dendritic cells (DCs), loss of XBP1 led to the reduction of IFN-α production in response to treatment with the TLR2 agonist CpG, causing the ER stress-associated cell death ([@B135]). Furthermore, XBP1s also stimulate the expression of the pro-inflammatory cytokines, such as IL-6, IL-15, and TNFα in splenic cells, multiple myeloma cells, and macrophages ([@B51], [@B134], [@B144], [@B167], [@B184]). Interestingly, IRE1α activation differentially regulates the expression of the pro-inflammatory cytokine IL-1β gene *via* activation of glycogen synthase kinase-3β ([@B51]).

In addition to XBP1s, IRE1α's RIDD activity triggers the production of type I IFNs. The RIDD generates single-strand mRNA fragments that lack 5′caps or 3′ poly (A) tails; these fragments activate retinoic inducible gene-I (RIG-I) protein. Further, RIG-I activates the cell-autologous inflammatory response through the mitochondria-associated antiviral system producing, IFN-β and other cytokines *via* the IFN and NFκB pathways, respectively ([@B98], [@B185]). Further, RIDD action causes sterile inflammation and apoptosis by increasing TXNIP mRNA stability *via* degradation of the TXNIP destabilizing microRNA miR-17 ([@B128]). This leads to an increase in the TXNIP protein level, which is known to activate the NLRP3 inflammasome, leading to caspase-1 activation through procaspase-1 cleavage and then production of IL-1β and IL-18 ([@B128], [@B186]). The NLRP3 inflammasome-mediated immune response has been identified in various autoinflammatory and metabolic diseases ([@B187]). However, in some cases, many circulating pro-inflammatory cytokines, such as IL-1, IL-6, IL-8, and TNFα, trigger ER stress-mediated IRE1α activation ([@B188]).

Furthermore, both XBP1s and the RIDD activity of IRE1α play roles in conventional dendritic (cDC) cells and MHC class-I antigen presentation. IRE1α-induced XBP1s in airway epithelial cells increase miRNA-346, which inhibits the translation of antigen peptide transporter 1 (TAP1), a necessary component for the MHC class I subunits and peptides assembly ([@B189], [@B190]). The reduction of TAP1 affects the MHC class I linked antigen presentation during ER stress or disease pathogenesis ([@B191], [@B192]). In addition, RIDD activity inhibits the MHC class I antigen presentation in CD8^+^ cDCs by degrading the crucial component of the MHC class I machinery: transporter associated with antigen processing binding protein (TAPBP) mRNA ([@B139]). These functions of IRE1α indirectly affect the activity of CD8^+^ T-cells, which recognize MHC class I peptides during the cytotoxic process.

Implications of IRE1α in ER Stress-Mediated Autoimmunity {#S4-2}
--------------------------------------------------------

IRE1α plays a major role in ER stress-mediated autoimmunity development possibly through five different mechanisms (Figure [3](#F3){ref-type="fig"}): including misfolded proteins identification by autoreactive immune cells, peptides released from apoptotic cells acting as neoantigens/autoantigens, disturbed immune-tolerance mechanisms increases ERAD-associated proteins that give the survival advantage to autoreactive cells ([@B193]), and reduced antigen presentation.

![Potential mechanisms of IRE1α in the development of autoimmune diseases. IRE1α activation by environmental factors or gene mutations that induce endoplasmic reticulum (ER) stress can lead to autoimmune disease development through various pathways. Spliced XBP1s increases the expression of the microRNA miR-346, which binds to the 3′-UTR of transporter associated with antigen processing (TAP) mRNA, leading to TAP mRNA decay. This reduces MHC class I complex formation and antigen presentation. XBP1s increases the expression of ER degradation-enhancing α-mannosidase-like protein and homocysteine-induced ER protein, leading to enhanced ER-associated degradation (ERAD), which can lead to autoimmune disease by increasing immune cell survival especially that of fibroblast-like synoviocytes. Misfolded proteins may act as autoantigens; for example, human leukocyte antigen B27 (HLA-B27), immunoglobulin binding protein (BiP), and pro-insulin. IRE1α has a role in the increased expression of BiP, and pro-insulin during stress and these proteins may act as autoantigens/neoantigens. IRE1α activation during the response to misfolded HLA-B27 misfolded response may contribute to autoimmunity in ankylosing spondylitis. ER stress or toll-like receptor-activated IRE1α mediates the production of pro-inflammatory cytokines through c-Jun N-terminal kinase, such as NFκB, XBP1s, and regulated IRE1α-dependent decay (RIDD), which increases the pathogenesis in autoimmune diseases. RIDD activity reduces MHC class I antigen presentation by reducing TAPBP protein synthesis. In addition, RIDD-mediated activation of nucleotide-binding domain, leucine-rich-containing family, and pyrin domain-containing-3 inflammasomes leads to increased secretion of IL-1β and IL-18, which increase the T-helper-1 cell immune response, which is characteristic of many autoimmune diseases. Furthermore, through inhibition of IRE1α, either with small chemical molecules, such as 8-formyl-7-hydroxy-4-methylcoumarin (4μ8c), sunitinib, imatinib, or by enhancing expression of negative regulators of IRE1α such as fortilin, it may be possible to reduce the progression of autoimmune diseases.](fimmu-09-01289-g003){#F3}

The first mechanism, in which misfolded proteins can generate an immunogenic response, has been observed in Akita mice, an experimental model for the autoimmune disease type 1 diabetes (T1D). A point mutation (Ins2, C96Y) caused pro-insulin to be misfolded and to accumulate in the pancreatic β cells, which led to UPR activation, inflammation, and ultimately β cell apoptosis ([@B194], [@B195]). Notably, IRE1α has a crucial function in the generation of the Akita mouse phenotype: inhibition of IRE1α's kinase function mitigates the disease phenotype ([@B196]). Furthermore, in ankylosing spondylitis, the human leukocyte antigen B27 (HLA-B27) protein is prone to be misfolded, even under physiological conditions ([@B197], [@B198]). The abnormally folded HLA-B27 is involved in autoimmune diseases in two ways: either it is expressed on the cell surface as an autoantigen, inducing an autoimmune response, or it causes the pro-inflammatory immune response by activating the UPR ([@B197]--[@B200]). The IL-17 and IL-23 cytokines including IL-23R are highly activated during HLA-B27 misfolding and UPR activation ([@B198], [@B201]). The production of these cytokines during HLA-B27-induced UPR is mainly contributed from the IRE1α/XBP1s pathway, which enhances IL-23 production during ER stress ([@B202], [@B203]). In addition, IFN-α, IFN-β, or TNFα stimulation in HLA-B27 overexpressing transgenic rats enhanced the BiP and spliced *XBP1* compared to wild-type rats ([@B201], [@B204]). Furthermore, in severe UPR, IRE1α-mediated cell apoptosis would also contribute in the autoimmune response, as apoptotic cells that contain self-antigens known to act as neoantigens induce autoantibody production ([@B205], [@B206]).

In the second mechanism, the ER chaperone protein GRP78 can act as an autoantigen and also known to evoke autoreactive response of B and T-cells ([@B49]). IRE1α/XBP1s may contribute to this process through increasing the GRP78 level of expression during ER stress ([@B207]). In the case of rheumatoid arthritis (RA), high expression of BiP in the synovium selectively triggered synovial T cells ([@B208], [@B209]). In support to this, autoantibodies of GRP78 were found in 80% of patients with RA ([@B210]).

In the third mechanism, defects in the immune tolerance mechanism in IECs may contribute to the progress of inflammatory colitis ([@B211]). IRE1β is highly expressed in these cells; interestingly in a study of IRE1β^--/--^ mice, BiP and XBP1s expression levels were increased in IECs indicating ER stress activation ([@B63], [@B101]). In addition, IRE1β^−/−^ mice with dextran sodium sulfate-induced colitis in showed intestinal inflammation earlier than in control mice ([@B62]). This is due to the increased permeability of IECs in IRE1β^−/−^ mice which exacerbated their colitis.

The fourth mechanism, may involve increasing the viability of autoreactive cells through the ERAD pathway, enhancing the autoimmune response during ER stress; this is known to reduce the misfolded proteins, easing the ER folding process, and reducing the apoptosis ([@B212]--[@B214]). The IRE1α/XBP1s pathway increases the expression of several ERAD-associated proteins and contributes to the establishment of homeostasis, further enhancing survival. One of the best examples of this mechanism is synoviolin (SYvN1) in R. IRE1α/XBP1s upregulates ERAD genes and genes important for protein folding such as EDEM1 and protein disulfide isomerase-P5 ([@B81], [@B215]). In addition, ERAD-associated proteins such as EDEM and homocysteine-induced ER protein (HERP) are modified and behave as neoantigens during overloading of the ER ([@B47]). This could be one of the contributions in β cell ER stress-mediated neoantigens.

The fifth mechanism is through regulating antigen presentation and affecting Th-1 cell function. The main immune activity in nucleated cells to combat pathogens or tumor cell progression is antigen presentation. Disturbance in antigen presentation may lead to the development of autoimmune disease ([@B216]). ER has a key function in MHC class I antigen presentation: usually, peptides derived from pathogens or other antigenic peptides through processing by proteasome will be transported to the ER, where they bind molecules of MHC class I, which exhibit them on the surface of cytotoxic T lymphocytes or CD8^+^ T-cells for the surveillance ([@B217], [@B218]). This binding to MHC class I molecules is required for the functioning of ER proteins, tapasin, and TAP ([@B189], [@B190], [@B219]). IRE1α activity affects this process during stress by decreasing TAP protein. IRE1α-mediated XBP1s increase the expression of miR-346, which directly represses the translation of TAP and other MHC class I-related mRNAs ([@B189], [@B190], [@B192]). Subsequently, the reduction of TAP protein leads to defects in MHC class I complex formation and thereby reduces antigen presentation. Interestingly, miR-346 increases the autoimmune response by regulating IL-8 release from activated synoviocytes in RA ([@B220]), and in addition, high expression of miR-326 is found in patients with T1D and ongoing islet autoimmunity ([@B221]). In addition, RIDD activity is also implicated in the reduction of MHC class I antigen presentation in CD8^+^ cDCs. IRE1α cleaves the crucial MHC class I machinery component, TAPBP mRNA, and reduces the antigen presentation ([@B139]), which results in autoimmunity. In support to this mechanism, a report showed that the reduced expression of MHC class I molecules on lymphocytes/lymphoid cells resulted in autoimmunity ([@B222]). Furthermore, in another study, the MHC class I molecules of abnormal expression on antigen-presenting cells resulted in the activation of autoreactive T-cells ([@B223]). These studies suggest that IRE1α activities interfere with the appropriate development of MHC class I molecules, which are necessarily required for self-immune tolerance; this also enhances the chances of development of autoimmune diseases.

In addition, IRE1α is implicated in increased IFN-γ release from Th-1 cells, which is a hallmark in the pathogenesis of atherosclerosis through IL-18 and IL-1β production from activated NLRP3 inflammasomes ([@B145]). The cytokines IL-1β and IL-18 play an important role in the polarization of Th-1 responses ([@B182]). Infiltration of these IFN-γ-producing Th-1 cells has been implicated in the development of autoimmune activity in mouse disease models of atherosclerosis ([@B181]), multiple sclerosis ([@B224]), and T1D as well as in human T1D ([@B225]).

IRE1α Involvement in Autoimmune and Inflammatory Diseases {#S5}
=========================================================

A faulty immune response can lead to the self-destruction of healthy cells or tissues, causing the development of autoimmune disorders ([@B226]). Immune cells target the modified self-cellular components as antigens and induce severe inflammatory responses, which normally lead to cell death ([@B18], [@B227]). There are a number of causative agents, such as oxidative stress; metabolic disorders; genetic factors; ER stress; dysregulation of production of cytokines, such as ILs, IFNs, and TNFα; and auto reactive T-cells; all of these are the hallmarks of autoimmune diseases ([@B193], [@B226]). However, in this section, we highlight the possible mechanisms of IRE1α's contribution to the progression of autoimmune diseases such as T1D, RA, inflammatory bowel disease (IBD), vitiligo, systemic lupus erythematosus (SLE), and scleroderma (Table [2](#T2){ref-type="table"}).

###### 

Possible mechanisms of IRE1α involved in different autoimmune diseases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of disease                    IRE1α downstream mechanisms                                                                                                                                                                                                                              Reference
  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  Type1 diabetes                     IRE1α-associated β cell damage occurs through activation of intrinsic apoptotic pathways\                                                                                                                                                                ([@B152]--[@B158])
                                     Increases insulitis through infiltered immune cells and proinflammatory genes through c-Jun N-terminal kinase (JNK)-AP1 and NFκB pathways\                                                                                                               
                                     β cell death through IRE1α/JNK/CCAAT-enhancer-binding protein homologous protein (CHOP)/DR5 and caspase 12 activation regulated IRE1α-dependent decay (RIDD)-mediated insulitis and β cell death through IL-1β and caspase-1 and caspase-2 activation\   
                                     Enhanced reactive oxygen species (ROS) and NO production through IRE1α/RIDD/thioredoxin-interacting protein (TXNIP)\                                                                                                                                     
                                     Potentiation of neoantigens development in β cells                                                                                                                                                                                                       

  Rheumatoid arthritis               Enhances proinflammatory cytokines, such as IL-β, IL-6, and TNFα in infiltered macrophages as well as in fibroblast-like synoviocytes\                                                                                                                   ([@B87], [@B88], [@B144], [@B159]--[@B161])
                                     IRE1α contributes increased inflammation and angiogenesis through toll-like receptors mediated activation in infiltered macrophages\                                                                                                                     
                                     Enhances synovial fibroblasts survival through endoplasmic reticulum-associated degradation genes upregulation                                                                                                                                           

  Systemic lupus erythematosus       Contributes to tissue apoptosis through IRE1α/XBP1s/CHOP and IRE1α/JNK/Bcl-2-associated X protein pathways                                                                                                                                               ([@B162], [@B163])

  Vitiligo                           Cause melanocyte loss through IRE1α/XBP1s-mediated cytokines production\                                                                                                                                                                                 ([@B128], [@B139], [@B164]--[@B166])
                                     IRE1α/XBP1s/TNFα pathway inhibits melanocyte stem cell differentiation\                                                                                                                                                                                  
                                     Enhances the recruitment of CD8^+^ T cells to skin lesions through increasing the levels of chemokines such as CXCL16\                                                                                                                                   
                                     Contributes in increased survival of CD8 α^+^ cDCs\                                                                                                                                                                                                      
                                     Contributes in ROS production at skin lesions through RIDD-mediated TXNIP and nucleotide-binding domain, leucine-rich-containing family, and pyrin domain-containing-3 inflammasome activation                                                           

  Inflammatory bowel disease         In inflammatory bowel disease, IRE1α contributes to secondary consequences of the disease by inducing the JNK and NFκB-mediated cytokines productions                                                                                                    ([@B167]--[@B169])

  Systemic sclerosis (scleroderma)   Activated IRE1α/XBP1s pathway in myofibroblasts contributes ER biogenesis, which helps in adaptation to increased protein folding requirement in myofibroblasts\                                                                                         ([@B170], [@B171])
                                     IRE1α/XBP1s pathway may also contribute in efficient protein folding by providing ER chaperones, such as glucose-regulated protein 78\                                                                                                                   
                                     IRE1α/RIDD pathway degrades miRNA-150, a repressor αSMA and collagen I and IV expression, which results in enhanced fibrosis\                                                                                                                            
                                     IRE1α/JNK/AP1 and IRE1α/NFκB pathways possibly involved endothelin-1 expression in systemic sclerosis                                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Type 1 Diabetes {#S5-1}
---------------

Type 1 diabetes is a chronic autoimmune disorder characterized by reduced insulin levels and increased blood glucose/hyperglycemia due to autoantigen-induced destruction of pancreatic islet β cells. Subsequently, the burden on the surviving β cells increases ([@B228], [@B229]), which augments the pathologic state of the T1D, which may be due to the ER stress-mediated inflammatory response and also the infiltration of autoreactive immune cells ([@B230]). Normally, β cell loss occurs due to impairment in the PTM of endogenous proteins and due to the production of pro-inflammatory cytokines by infiltrated immune cells ([@B41], [@B231], [@B232]).

Although genetic weakness is a major critical risk factor for β cell destruction ([@B233], [@B234]) and other inflammation inducing environmental factors, such as age, viral infection, drug exposure, ROS, and metabolism fuel the onset or progression of T1D ([@B10]). In addition to these environmental triggers, the β cells inherent secretory function even in physiological conditions predisposes them to significantly higher levels of ER stress and UPR activation, compared to other nonsecretory cells ([@B18], [@B235]). Many factors such as pro-inflammatory cytokines, high glucose, and free fatty acids are known to expose β cells to ER stress in Ref. ([@B236]--[@B238]). Furthermore, these factors induce changes in β cell identity, which makes β cells more vulnerable to autoimmune destruction and results in the progression of T1D ([@B239]). Notably, the expression levels of ER stress markers CHOP and BiP are higher in pancreatic islets from T1D individuals compared to healthy individuals ([@B240], [@B241]). In addition, the ER stress-induced misfolded insulin complex can function as a neoantigen and is recognized by autoreactive T-cells ([@B242]). Therefore, high level of ER stress would be a common factor that precedes the pathogenesis of T1D ([@B18], [@B50]). These facts signify the association of ER stress in the occurrence of T1D.

β cells express high levels of IRE1α, which is necessary for pro-insulin synthesis ([@B243], [@B244]). In one study, specific deletion of IRE1α in β cells impaired proliferation, proinsulin synthesis processing, and secretion ([@B245]). However, in other studies, prolonged activation of the IRE1α pathway in chronic exposure to hyperglycemia triggered alternative molecular pathways along with XBP1s, which led to β cell dysfunction and apoptosis ([@B99], [@B246], [@B247]). In T1D, IRE1α-associated β cell damage can occur through two processes. First, prolonged ER stress in the β cells due to their high levels of secretion, can induce the intrinsic apoptotic pathway by increasing pro-apoptotic and inflammatory molecules ([@B152], [@B153]). A second process is mediated by insulitis: during the initial phases of the disease immune cells, such as macrophages, DCs, T-cells, and natural killer (NK) cells infiltrate the islets and release pro-inflammatory cytokines, such as IL-1β, TNFα, IFN-γ, IL-17, IL-23, IL-24, and also free radicals ROS and nitric oxide ([@B144], [@B152], [@B248]). These cytokines enhance β cell apoptosis in T1D ([@B158], [@B249]) by inducing ER stress-mediated activation of AP-1, NFκB, XBP1s, and JNK ([@B54], [@B238]). In addition, pro-inflammatory cytokines stimulate β cells to secrete cytokines and chemokines. These attract T-cells, which then infiltrate the islets, which causes β cell destruction in T1D ([@B152], [@B153]).

IRE1α activates the JNK-AP1 and NFκB pathways, which increases the expression of the pro-inflammatory genes, such as IL-β, TNFα, and IL-6 and regulate the transition from adaptive UPR to apoptotic β-cell death during diabetes ([@B144], [@B248]). Additionally, IRE1α-mediated JNK activation upregulates CHOP and causes β cell death through IRE1α/JNK/CHOP/DR5 expression ([@B154], [@B155]). In the non-obese diabetic mouse (NOD) mice study, the expression of NFκB target genes and ER stress markers increased before the development of hyperglycemia ([@B16]), which indicates the inflammatory-mediated IRE1α contribution in T1D. In T1D disorder, pro-inflammatory cytokines are initial mediators of β cell apoptosis ([@B250]). Furthermore, the IRE1α/XBP1s pathway also increases NFκB activation by increasing the proteasome-mediated degradation of Forkhead box O1 (FoxO1), an inhibitor of NFκB (Figure [2](#F2){ref-type="fig"}) ([@B249], [@B251], [@B252]). In contrast, Hassler et al. recently demonstrated that the IRE1α/XBP1s absence in the islets of adult mouse caused the increase of IL-1β, iNOS, and chemokine (C-X-C motif) ligand 2 (CXCL2) after treatment with high glucose ([@B244]). These studies demonstrate that the inflammatory effects of XBP1s are differentially regulated and may depend on the stress intensity. IRE1α also enhances IL-23 expression in DCs ([@B203]). This causes the massive T-cell infiltration within the islets and ultimately results in β cell destruction. Furthermore, in a rat model of virus-induced T1D, IRE1α specifically activated caspase-12 and caused β cell death and thus contributed to virus-induced autoimmune T1D ([@B253]).

In addition to JNK and NFκB activation, RIDD activity also propagates insulitis and diabetes-related β cell death. IRE1α/RIDD mediates cytokine IL-1β production, and caspase-1 and -2 activation through TXNIP, which is activated by the NLRP3 inflammasome by degradation of TXNIP repressor miRNA ([@B128]), and this could also integrate mitochondria-mediated inflammation ([@B129]). TXNIP is known to be associated with progression of T1D and is one of the genes, which upregulated during conditions of hyperglycemia in case of human islet cells as well as in animal models of diabetes ([@B156], [@B157]). However, islets from NLRP3^−/−^ and caspase-1^−/−^ mice were not protected from ER stress or high glucose-induced death ([@B254]), and knocking out of the NLRP3 inflammasome in Akita mice also did not show the protection to ER stress-induced diabetes progression or β-cell damage ([@B255]). These studies indicate three possibilities: first, that the NLRP3 inflammasome is dispensable for β cell death; second that it may be an intermediate molecule in cytokine production; and third, that its role could be context dependent, because elimination of NLRP3 protects against obesity-induced pancreatic damage ([@B256]).

Furthermore, IRE1α may potentiate the development of neoantigens in β cells. Exposure of pancreatic β cells to the pro-inflammatory cytokines IL-1β, TNFα, and IFNs induce ER calcium depletion ([@B257]). This depletion results in abnormal PTMs through the Ca^2+^-dependent PTM enzyme Tgase2 ([@B18]). Furthermore, abnormally folded self-peptides act as neoantigens and increase β cell immunogenicity. These peptides are recognized by autoreactive T-cells, which then destroy the β cells, furthering the pathogenesis of T1D ([@B18]). Human islets and human EndoC-βH1 cells exposed to IFN-α showed impaired insulin production *via* increased ER stress and increased XBP1s levels ([@B158]). Furthermore, predisposition of pancreatic β cells to ER stress in cases of insulin resistance and obesity exacerbates the activation of IL-1β, TNFα, and NFκB ([@B252]). Therefore, the initial activation of IRE1α by mild ER stress exposes β cells to a feedback loop of exacerbated inflammatory responses, causing β cell death and subsequent T1D. These studies suggest that the tight regulation of IRE1α activation, in β cells, is crucial for maintenance of their function. Therefore, a better understanding of IRE1α's possible role in T1D would open the gate for the discovery of therapeutic options.

Rheumatoid Arthritis {#S5-2}
--------------------

Rheumatoid arthritis is a chronic autoimmune disorder, in which immune system attacks own body's tissue and cause bone and joints deformities. This disorder is commonly defined by increased synovial cell proliferation, inflammatory cell infiltration, angiogenesis, and damage in the lining of joints ([@B258]). Fibroblast-like synoviocytes (FLS) are key effector cells: they release cytokines and proteases that contribute to cartilage damage ([@B259]). The pro-inflammatory cytokines TNFα and IL-1β are significantly upregulated in RA. Synovial fibroblasts in RA are resistant to apoptosis ([@B260]), but the mechanisms for this are not yet clear. Recent studies have shown the possible involvement of ER stress due to the increase in the ER stress marker GRP78 in synoviocytes. GRP78 has been implicated in the pathogenesis of RA synovium and synovial cells because of its contribution to synoviocyte proliferation and to angiogenesis, and it can also act as an autoantigen ([@B17]). In mice with *Grp78* haploinsufficiency induction of arthritis was suppressed, but GRP78 injection failed to induce arthritis in several strains of rats and mice ([@B210]). Additionally, ER stress is well recognized for its functions in cell survival and pro-inflammatory properties; these effects are usually mediated through IRE1α, PERK, and ATF6 ([@B79]). Therefore, IRE1α plays a vital role in cell survival, apoptosis, cytokines production, and angiogenesis. Understanding the role of IRE1α in synoviocyte antiapoptotic mechanisms and cytokines production might aid in the design of possible treatment strategies.

Cell surface TLR2 and TLR4, and endosome TLR7, play a very important role in RA pathogenesis by increasing the inflammation and angiogenesis ([@B261]). The mechanism through which toll-like receptors (TLRs) induce pathogenesis may be dependent on the IRE1α/XBP1s signaling pathway. The activation of IRE1α/XBP1s signaling found in cells of synovial fluids, obtained from patients with RA, can be due to the TLRs in macrophages, which are usually significantly well expressed in synovial fibroblasts of RA patients ([@B160], [@B161]). In addition, TLRs specifically activated the IRE1α/XBP1s pathway and this is found to be essential for the optimal production of pro-inflammatory cytokines IL-1β, IL-6, and TNFα in macrophages as well as in FLS ([@B144], [@B159]) (Figure [3](#F3){ref-type="fig"}). In activated synovial fibroblasts of RA patients, XBP1s is highly expressed, but this expression appears to occur independently of ER stress. Instead it is activated through TLR2 and TLR4 ligation-induced IRE1α/XBP1s, leading to increased production of the pro-inflammatory cytokines TNFα and IL-6 ([@B144], [@B159]). This activity of IRE1α could have a special importance in pathogenesis of RA, because expression of TLR2 and TLR4 is distinctly high in the joints of patients with RA ([@B262]). Additionally, TLR7 is also implicated in XBP1 induction and IFNα production ([@B179]).

Toll-like receptors induced neovascularization in RA is also may be mediated through IRE1α/XBP1s pathway, which is known to upregulate the proangiogenic VEGF-A, IL-1β, IL-6, and IL-8 factors ([@B263]). This interrelation of TLRs and IRE1α in RA can further potentiate inflammation *via* increased leukocyte infiltration. Although TLRs are primarily for pathogen receptor recognition, they are also reported as sensing endogenous ligands, such as SNARE associated protein (SNAPIN) ([@B264]). In addition, the enhanced TLR2 ligand expression in synovial tissue macrophages has been found to have the importance in the pathogenesis of RA through SNAPIN ([@B265]). Therefore, by interference with TLR/IRE1α/XBP1s could be treatment strategy for RA.

Corroboration to above studies, in mice with experimental arthritis, deletion of the IRE1α gene specifically in myeloid tissue- or inhibition of IRE1α with 8-formyl-7-hydroxy-4-methylcoumarin (4μ8c) compound decreased the production of pro-inflammatory cytokines, which further subsidized the joint inflammation ([@B266]). This indicates that IRE1α/XBP1s signaling act as a focal point, where different stimuli are converge and function to maintain the activation of FLS. On the other hand, an earlier study reported that the reduction of IRE1α protected the FLS from apoptosis, which led to the enhanced proliferation of synovial cells and influenced the development of RA ([@B267]). Furthermore, a recent study reported that hyper-activation of IRE1α inhibited IL-4 and IFN-γ through reducing the *t-bet* and *gata-3* mRNA by its RIDD activity in palmitic acid-treated NK T-cells, thereby suppressing arthritis ([@B268]). These studies suggest that FLS in RA maintain an optimal level of IRE1α activation for survival, allowing XBP1s activity but avoiding hyperactivation of IRE1α-mediated apoptosis by promoting synoviolin1 (SYvN1)-associated IRE1α degradation. The pathogenesis of RA is mostly due to the activated synovial fibroblasts, showing enhanced survival and a destructive phenotype ([@B269]). This enhanced survival is thought to result from the dysregulation of UPR and ERAD ([@B212], [@B270], [@B271]). The IRE1α/XBP1s signaling pathway upregulates the ERAD genes during ER stress and may promote the synovial fibroblasts in RA ([@B81], [@B86]--[@B88]).

SLE or Lupus {#S5-3}
------------

Systemic lupus erythematosus is an autoimmune disease and it has been described by abnormal apoptosis of healthy tissue in multiple organs of the body, such as lung, heart, skin, kidney, and many other parts ([@B272]). SLE pathogenesis is a complex of genetic and environmental factors resulting in an overactive innate immune system, cytokine imbalance, autoantibody production, and abnormal B-cell and T-cell function ([@B273]). However, the exact cause of pathogenesis is still not clear. Recently, several studies have tried to establish how ER stress is involved because of its association with other autoimmune diseases, as well as with B-cell, and cytokine production. Additionally, HERP, an ER stress-associated protein has been observed as an autoantigen for anti-DNA antibodies in SLE ([@B274]). Further characterization of ER stress-related genes in patients with SLE demonstrated increased expression of XBP1s and CHOP ([@B162]). Bone-marrow derived mesenchymal stem cell apoptosis in SLE patients was found to be mediated through the IRE1α/JNK/BaX pathway ([@B163]). Differentiation of antibody producing B-cells requires the IRE1α/XBP1s axis: B-cell-specific deletion of *XBP1* protected mice from developing a lupus-like disease ([@B275]). These studies indicate that abnormalities in the IRE1α/XBP1s axis may contribute to SLE pathogenesis and could be a target for the treatment. However, some more work needs to be carried out to better appreciate the role of IRE1α in SLE pathogenesis.

Inflammatory Bowel Disease {#S5-4}
--------------------------

Inflammatory bowel disease is generally characterized by recurrent, destructive inflammation of the gastrointestinal tract ([@B276]) and comprises both Crohn's disease and ulcerative colitis forms of IBD. It is estimated to affect millions of people worldwide ([@B277]). The definite causes of IBD, either inflammatory-mediated or autoimmune-mediated responses, are highly debated ([@B278]). However, there is ample evidence regarding the involvement of autoimmunity in IBD pathogenesis ([@B279], [@B280]). Anti-TNFα drug molecules have shown the positive efficacy against IBD; in fact, TNFα is one of the dominant pro-inflammatory cytokines in autoimmune diseases ([@B281], [@B282]). These studies indicate the possible involvement of autoinflammation in IBD. The loss of tolerance to indigenous enteric flora due to genetic or environmental factors, defects in T-cell function, excessive mucosal DCs, and autoantigens results in IBD pathogenesis ([@B278]). ER stress in the intestinal epithelial goblet and Paneth secretory cells is another cause of IBD. ER stress has been reported in IBD inflammation, and all three signal transducing wings (ATF6, IRE1, and PERK) of the UPR are activated ([@B283]). The IRE1α role in IBD is focused upon here: as mentioned earlier, both human isoforms IRE1α as well as IRE1β are ubiquitously expressed in the epithelium of the gastro-intestine. Furthermore, IRE1α involvement in optimized production of mucin in intestinal goblet cells indicates the requirement of IRE1α function in the goblet cells ER homeostasis ([@B101]). The function of IRE1α/XBP1s signaling pathway is necessarily required for the optimal function and survival of intestinal secretory cells, as such cells are more susceptible to ER stress due to their function ([@B284]). Additionally, impairment of the IRE1α/XBP1s axis due to stress leads to the secondary consequence of inflammation ([@B167]). With conditional *XBP1* gene knockout mice, specifically at epithelium of small and large intestine Paneth cells as well as goblet cells disappeared ([@B92]). This deletion further resulted in IRE1α-activated JNK and NFκB-mediated inflammation, leading to development of the features of human IBD. In addition, the supportive blockade of NFκB activation or the genetic deletion of IRE1α in IECs, protected *Xbp1*ΔIEC mice from spontaneous enteritis ([@B92], [@B168], [@B169], [@B284]). p-JNK was increased when XBP1-deficient epithelium was exposed to bacterial antigen, flagellin, and TNFα; a major pathogenic cytokine in IBD was increased. Deficiency of IRE1β and XBP1 within the intestinal epithelium caused the spontaneous inflammation that enhanced the susceptibility to colitis during the treatment with dextran sodium sulfate ([@B62], [@B92], [@B285]). This could be due to another isoform, IRE1α, as it was observed that, in the absence of XBP1, IRE1α activity augmented JNK phosphorylation. Added to this, IRE1β^−/−^ mice showed accumulation of abnormal MUC2 inside the ER of goblet cells ([@B101]). These result in the IL-23 and Th-17 cell inflammatory axis-mediated UPR activation and spontaneous ulcerative colitis ([@B286], [@B287]).

Further, IRE1α accumulation in autophagy defective Atg16l1^ΔIEC^ mice increased Crohn's disease ileitis ([@B285]). In contrast, disruption of IRE1α gene in IECs also led to spontaneous colitis, loss of goblet cells, intestinal epithelial barrier function, and IBD in mice ([@B288]) but the colitis could have been due to the lack of XBP1s protein. XBP1 splicing is necessary: in a study of patients with ulcerative colitis, decreased XBP1s levels were observed ([@B289]). A recent study reported that the use of the XBP1 agonist HLJ2 inhibited inflammation and ameliorate the ulcerative colitis ([@B290]). IRE1α, IRE1β, and XBP1 are very much required for the IECs homeostasis maintenance and also have a functional role in defending against IBDs. However, during severe conditions or during damage caused by other factors, the IRE1α pathway may contribute to extend inflammation and death of IECs.

Vitiligo {#S5-5}
--------

Vitiligo is a condition characterized by white patchy areas on the skin, appeared due to the death of pigment producing melanocytes. It affects approximately 1% of the population worldwide ([@B291]). It is a multifactorial disorder with a complex pathogenesis. Oxidative stress and autoimmune mechanisms play major roles in the onset and progression, respectively ([@B164], [@B292]). The mechanisms, which are involved in the triggering of the disease and the spread of lesions, still need to be clarified. However, increased expression of local and systemic cytokines, oxidative stress, and expansion of the ER in melanocytes at the margins of lesions in vitiligo patients indicates the possible involvement of ER stress in pathogenesis ([@B293]). Treating melanocytes with chemical inducers of vitiligo, upregulated the expression of XBP1s, and its activation enhanced the release of IL-6 and IL-8 ([@B164]). Additionally, polymorphism in the *XBP1*gene increases the risk of developing vitiligo ([@B294]). Thus, IRE1α/XBP1s activity in melanocytes contributes to cytokine-associated immune reactions and also melanocyte loss following the onset of vitiligo due to environmental stressors or ROS. TNFα released through IRE1α/XBP1s may inhibit melanocyte stem cell differentiation ([@B165]).

Furthermore, CD8^+^ T-cells are key effectors of melanocyte destruction in patients with vitiligo ([@B295], [@B296]). The recruitment of CD8^+^ T-cells to skin lesions is carried out by the IFN-γ-mediated T-cell chemokine receptor, C-X-C motif chemokine receptor 3 (CXCR3), and its ligands CXCL9, CXCL10, and CXCL11, which are abundant in skin biopsy specimens from patients with vitiligo ([@B297]). Blockade of this pathway ameliorated the vitiligo in mice as well as in human subjects ([@B298], [@B299]). IRE1α/XBP1s signaling in stressed keratinocytes increased the level of CXCL16, a major chemokine involved in CD8^+^ T-cell recruitment ([@B166]). Additionally, IRE1α/XBP1s also contributes to homeostasis and survival of CD8α^+^ conventional DCs ([@B139]). Chemically induced skin inflammation in a mouse model showed activation of NLRP3 inflammasome and the downstream effector IL-1β in the milieu of vitiligo ([@B300]). IRE1α activity also may lead to activation of NLRP3 inflammasome and release of ROS through regulation of TXNIP expression ([@B128]). All these data show the possible involvement of ER stress-induced IRE1α in pathogenesis of vitiligo. However, more studies in relation to IRE1α and the expression patterns of its downstream molecules in clinical samples of vitiligo are necessary for treatment development.

Systemic Sclerosis (Scleroderma) {#S5-6}
--------------------------------

IRE1α involvement has also been observed in systemic sclerosis, a complex connective tissue autoimmune diseases, characterized by multi-organ fibrosis due to the fibroblast dysfunction resulted in increased collagen and other extracellular matrix components accumulation in skin and internal organs ([@B301], [@B302]). Increased expression of IRE1α-mediated GRP78 and XBP1s were observed in a subtype of systemic sclerosis, pulmonary arterial hypertension ([@B170]). Furthermore, activation of IRE1α contributes to systemic sclerosis through both RIDD and XBP1 splicing activities. RIDD activity degrades the miRNA-150, a repressor of fibrosis components αSMA, collagen I and IV, which influences the myofibroblast formation ([@B171]). Spliced XBP1 helps the myofibroblasts in the ER biogenesis and enlargement ([@B303]). This activity is required for the myofibroblasts during extracellular matrix proteins secretion and increased ER volume functions as an adaptive mechanism for increased protein folding requirement ([@B171], [@B303]). In the same study, it was shown that, inhibition of IRE1α with 4μ8C prevented the TGF-β induced myofibroblast activation and reduced the fibrosis of liver and skin in animal models. Interestingly, inhibition of IRE1α reverted the diseased phenotypes of myofibroblasts isolated from patients with scleroderma ([@B171]). Therefore, targeting the IRE1α with the inhibitors such as 4μ8C could be a possible treatment approach for patients with systemic sclerosis. In addition, endothelin-1 plays a very important functional role in progression of systemic sclerosis ([@B304], [@B305]). This endothelin-1 expression is also regulated by JNK/AP1 and NFκB pathways ([@B306]--[@B308]). As mentioned above, IRE1α activation increases the JNK/AP1 and NFκB pathways-mediated transcription. Therefore, it could be possible that IRE1α-mediated endothelin-1 expression has a role in systemic sclerosis pathogenesis.

IRE1α in Other Autoimmune Diseases {#S5-7}
----------------------------------

In addition, IRE1α importance can be expected in other autoimmune disorders including Sjögren's syndrome (SS). In this disease, secretory cells are the main type affected, which leads to reduced secretion, resulting in pathologies such as dry mouth and dry skin ([@B309]). Normally, salivary gland acinar cells, due to their secretory function, are highly susceptible to ER stress under physiological circumstances due to their high rate of protein synthesis ([@B310]--[@B312]). Therefore, activation of IRE1α and other UPR molecules is expected due to their regulation of secretion and also to alleviate the ER folding load ([@B87], [@B313]). Further, in patients with SS, accumulation of mucins caused dilatation of the ER, and high levels of pro-inflammatory cytokines were observed in SS patients ([@B214]). However, there are fewer data available regarding the IRE1α association with SS. Future studies aiming to characterize the role of IRE1α and its downstream molecules in SS would pave the way for understanding the causes.

IRE1α influences can also be surmised in myasthenia gravis, an autoimmune disease of the neuromuscular junction characterized by muscle fatigue ([@B314]). Recently, ER stress has also been implicated in myasthenia gravis, due to the increased expression of ER chaperons GRP78 and GRP94 in skeletal muscle from myasthenia gravis ([@B315], [@B316]). IRE1α/XBP1s, as a potential pathway in ER stress-mediated GRP78 and GRP94 expression ([@B317]), possibly have a role in the pathogenesis of myasthenia gravis; however, there is no direct evidence of IRE1α pathway yet.

Furthermore, IRE1α-induced apoptosis has been suspected in the thyroid cytotoxicity that is induced by excessive iodide and fluoride. High levels of IRE1α and XBP1s were observed in the Nthy-ori 3-1 thyroid cell line upon exposure to iodide and fluoride ([@B318]). Interestingly, ER stress activation reduced the expression of genes involved in thyroid hormone synthesis. FRTL-5 thyrocytes treated with tunicamycin, an ER stress inducer, showed increased levels of XBP1 and other UPR molecules but also showed a reduction in thyroid hormone synthesis. This indicates the role of ER stress-activated molecules in thyroid hormone synthesis ([@B319]). However, IRE1α has not been studied extensively in this disease.

Modulation of IRE1α Activities in Autoimmune Disease Treatment {#S6}
==============================================================

The different magnitudes of IRE1α activity under physiological and pathological conditions suggest that the activity levels of its downstream substrates XBP1, ER localized mRNA, miRNA, JNK, and NFκB are crucially dependent on the stress intensity, tissue type, and attributes of the pathology. Interestingly, the structure--activity relationship studies have demonstrated that an allosteric association within the two enzymatic kinase and RDs of IRE1α, which provided the opportunity to modulate its downstream activities ([@B99], [@B320], [@B321]). Kinase inhibitors/ATP-competitive molecules have been studied to examine how they modulate the RNase activity of IRE1α. Type 1 kinase inhibitors, such as 1NM-PP1, APY29, staurosporine, and sunitinib inhibit autophosphorylation but induce change to the active conformation in both kinase and RDs. Type II kinase inhibitors are kinase-inhibiting RNase attenuators, these allosterically block both kinase and RNase activity by disrupting oligomers of IRE1α ([@B322]). Since IRE1α plays a role in both adaptive pro-survival and pro-apoptotic activity, modulating it through inhibition or activation will yield different clinical benefits depending on the type and state of the disease. Many studies have been reported on the application of small chemical modulators in other disease, such as cancer ([@B145], [@B323], [@B324]). Inhibition of IRE1α with optimized application of KIRA, KIRA6, in rat promoted the cell viability and protected photoreceptor cells function under ER stress ([@B196]). Additionally, KIRA6 application in Akita diabetic mice protected pancreatic β cells through improved insulin production and reduced hyperglycemia ([@B196]). The details of various chemical modulators of IRE1α have been reviewed elsewhere ([@B325]). Treatment of ApoE knockout mice with STF-083010 and 4μ8C, which are IRE1α-specific inhibitors, reduced the hyperlipidemia-induced immune response and alleviated atherosclerosis. Furthermore, treatment with liraglutide, a glucagon-like peptide 1 analog, protected INS-1 cells, a pancreatic cell line, from thapsigargin-induced ER stress-associated cell apoptosis, mainly by suppressing the PERK and IRE1α pathways ([@B326]). Application of resveratrol, protected rats against acute kidney injury through inhibition of IRE1α phosphorylation and IRE1α/NFκB pathway-triggered inflammatory response ([@B327]).

However, application of IRE1α inhibitor in few experimental models of autoimmune diseases showed the glimpse of treatment possibilities. Treatment with 4μ8c in a mouse inflammatory arthritis model ([@B266]) and systemic sclerosis ([@B171]) had suppressed the disease phenotypes. In another recent study, application of imatinib, an anti-neoplastic tyrosine kinase inhibitor, protected non-obese diabetic (NOD) mice from T1D by interfering with the interaction between ABL kinase and IRE1α, resulting in reduced enzyme activity ([@B328]). In addition to the above small molecule applications, there are some intrinsic molecules that negatively regulate IRE1α activity during stress. However, these molecule interactions are context dependent. Briefly noted here, BaX inhibitor-1, an antiapoptotic, ER stress inhibition molecule that negatively regulates IRE1α-mediated XBP1 splicing and JNK activation, protects against ER stress-associated cell apoptosis ([@B329], [@B330]). In RA, SYVN1 overexpression inhibits IRE1α-mediated cell death by promoting proteasome degradation. This leads to enhanced survival and overgrowth of synovial cells, which escalates the pathogenicity of synovial cells in RA ([@B267]). Ubiquitin D expression in a type 1 diabetic condition influenced by IL-1β and IFN-γ reduced the IRE1α/JNK axis-mediated inflammation in cytokine-exposed β cells ([@B331]). However, IRE1α is still under investigation for target-specific drug development. In addition, fortilin, a pro-survival molecule, inhibits both kinase and endoribonuclease activities of IRE1α. Treatment protected mice from ER stress-induced liver failure ([@B332]). However, the development of therapeutic strategies for modulating IRE1α is still under investigation. Since this molecule plays a role in both cell survival and death, it is very crucial to consider its transition from the pro-survival to the pro-death pathway in developing new therapeutic modes. Fine-tuning of the above mentioned small molecules and intrinsic modulators of IRE1α will probably pave the way forward.

Conclusion {#S7}
==========

Accumulating evidence from a variety of recent studies has demonstrated that ER perturbations affect the folding and PTMs of several proteins that develop as auto/neoantigens. Along with this, increased secretion of pro-inflammatory cytokines contributes to the development and pathogenesis of autoimmune diseases. In most cases, the emerging clues suggest that the activation of IRE1α could play a major role in autoimmune disorders. The *XBP1* splicing activities of IRE1α and its RIDD activity are especially known to contribute to the pro-inflammatory responses in several inflammatory disorders. Additionally, the release of AP-1 and NFκB-mediated pro-inflammatory cytokines augments pathogenesis. Furthermore, TLR-mediated activation of IRE1α/XBP1s in an ER stress-independent manner also contributes to the production of pro-inflammatory cytokines, exacerbating the disease condition. Recent studies on the design of small chemical molecules to modulate IRE1α activity are increasing the detailed understanding of IRE1α mechanisms and also may be of therapeutic benefit. Despite the success achieved with the application of small chemical molecules in experimental T1D and RA, more efforts in this direction would better pave the way to meet future challenges with regards to autoimmune disease treatment.
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